Erythropoietin Drugs Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Erythropoietin Drugs Market Trends and Insights

Rising Burden of Chronic Kidney Disease and Anemia

The erythropoietin drugs market is gaining from a growing chronic kidney disease (CKD) patient base rather than short-term pricing cycles. The Global Burden of Disease (GBD) Study 2025 reported 788 million adults living with CKD in 2025, compared with 378 million in 1990, expanding the long-term treatment pool for anemia management. KDIGO noted that anemia prevalence rises sharply with CKD progression and exceeds 90% in stage G5 across multiple cohorts, while the Indian Society of Nephrology’s 2025 guidance supports erythropoiesis-stimulating agent (ESA) initiation when hemoglobin falls below 10.0 g/dL.^{[2]Kidney Disease Improving Global Outcomes Anemia Work Group, “KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease,” Kidney International, kdigo.org} Separate GBD 2021-based modeling showed 63.75 million CKD-related anemia cases globally and projected a further rise by 2035, with South and Southeast Asia, Central Europe, and Sub-Saharan Africa carrying a high age-standardized burden.

Expanding Chemotherapy-Induced Anemia Supportive Care Use

The erythropoietin drugs market also benefits from sustained use in chemotherapy-induced anemia, particularly in palliative care settings. The WHO noted that anemia affects 30% to 90% of patients receiving chemotherapy, depending on tumor type and treatment stage, supporting demand across oncology care pathways.^{[3]World Health Organization, “Chemotherapy-Induced Anemia: Application to the 25th WHO Expert Committee on Selection and Use of Essential Medicines,” WHO, who.int} Current ASCO and ASH guidance supports ESAs for patients receiving non-curative chemotherapy when the treatment goal is to reduce transfusion need. A 2025 real-world study of Cresp, Dr. Reddy’s Laboratories’ darbepoetin alfa, found positive hemoglobin dynamics in 78.2% of 523 Indian patients on palliative chemotherapy, while oncology guidance also links intravenous iron use with better hematopoietic response when ESAs are prescribed.^{[4]Alaa El-Din Hassan et al., “Network Meta-Analysis of HIF-Prolyl Hydroxylase Inhibitors for Anemia in Dialysis-Dependent and Non-Dialysis CKD: Effects on Hemoglobin, Iron Markers, and Adverse Clinical Outcomes,” BMC Nephrology, springer.com}

Biosimilar Penetration in Price-Sensitive Hospital Procurement

Biosimilars are reshaping growth in the erythropoietin drugs market across hospital and public tender channels. Their impact extends beyond price erosion, as lower-cost supply enables dialysis networks to adopt treatments that previously could not sustain originator pricing. This trend is especially important in emerging procurement systems, where constrained nephrology budgets and unit economics influence formulary decisions. India, South Korea, and China continue to strengthen glycoprotein manufacturing capabilities, improving supply reliability and supporting broader tender participation across Asia, Africa, and Latin America.

Long-Acting ESA Adoption in Dialysis and Renal Clinics

Long-acting agents are adding a premium growth layer to the erythropoietin drugs market, even as short-acting categories face pricing pressure. Mircera, methoxy polyethylene glycol-epoetin beta, supports dosing every two weeks or once monthly in adults with CKD, reducing administration burden in dialysis and renal clinics. China advanced this trend when the National Medical Products Administration (NMPA) approved 3SBio’s Loncipoetin Alfa Injection in March 2026, with a reported 120-hour half-life and biweekly dosing for hemodialysis patients already receiving EPO therapy. The UK Kidney Association’s 2025 update noted that long-acting ESAs may be preferred in some non-hemodialysis patients where subcutaneous dosing helps preserve vein access, while KDIGO 2026 keeps methoxy polyethylene glycol-epoetin beta within mainstream treatment algorithms for dialysis patients.

Safety Concerns and Conservative Hemoglobin Targeting

Safety guidance continues to limit dosing intensity in the erythropoietin drugs market. KDIGO 2026 is expected to recommend against targeting hemoglobin levels above 11.5 g/dL in erythropoiesis-stimulating agent (ESA)-maintained patients due to risks such as stroke, thromboembolism, and hypertension. This limits dose escalation and moderates volume upside from the rising chronic kidney disease population, while oncology use remains restricted to non-curative settings due to survival and tumor progression concerns. The UK Kidney Association also recommends clinical review for ESA hyporesponsiveness instead of repeated dose escalation, further limiting per-patient spending.

Substitution Pressure From HIF-PHI and Other Non-ESA Alternatives

Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) products remain the most direct substitution pressure in the erythropoietin drugs market. A 2025 network meta-analysis in BMC Nephrology is expected to position roxadustat and daprodustat among the strongest agents for hemoglobin improvement and highlight daprodustat’s benefits on iron indices. These products reduce dependence on injections and cold-chain logistics, offering operational advantages in selected care pathways. However, KDIGO 2026 is expected to continue recommending ESAs before HIF-PHIs due to limited superior safety evidence and uneven regulatory acceptance, keeping substitution risk higher in China and parts of Europe than in markets with stronger ESA-first practice.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Biosimilar Expansion Changes the Revenue Mix

Biologics are expected to hold 58.34% of the erythropoietin drugs market share in 2025, supported by strong formulary positions for originator brands such as Epogen, Aranesp, NeoRecormon, and Mircera across developed healthcare systems. Their position reflects physician familiarity, established hospital and dialysis procurement patterns, and demand for treatment continuity in chronic anemia care. Biosimilars are the fastest-growing type and are projected to expand at a CAGR of 14.53% through 2031, driven by lower costs and improved access to erythropoiesis-stimulating agents (ESAs). India, South Korea, and China are central to this shift as manufacturers scale complex biologics production and expand exports, gradually shifting share from originators to biosimilars without reducing the treatment base.

By Product: Longer Dosing Intervals Support Product Differentiation

Epoetin alfa is expected to account for 35.45% of the erythropoietin drugs market in 2025, maintaining its position as the largest product category by revenue due to broad formulary access and sustained use across dialysis networks, hospitals, and oncology settings. Epoetin beta and methoxy polyethylene glycol-epoetin beta remain important adjacent categories across Europe, Japan, and chronic kidney disease (CKD) maintenance therapy, while Mircera continues to benefit from monthly maintenance dosing. The erythropoietin drugs market size for darbepoetin alfa is projected to grow at a CAGR of 13.67% through 2031, supported by weekly to biweekly dosing and use across multiple indications. Other products, including novel glycoengineered variants such as Loncipoetin Alfa from 3SBio, are expected to strengthen the premium long-acting tier, supported by adherence benefits and lower dosing frequency following its March 2026 approval in China.

By Application: Kidney Disease Remains the Core Demand Base

Kidney diseases are expected to represent a 43.24% share in 2025, making them the largest application in the erythropoietin drugs market due to the strong clinical link between CKD progression and anemia burden, especially among dialysis-dependent patients. KDIGO noted that anemia prevalence rises sharply as kidney function worsens and becomes very common in stage G5, while its guidance supports ESA initiation in CKD G5D patients when hemoglobin falls to 9.0 to 10.0 g/dL. Cancer is projected to record the fastest application growth at a CAGR of 12.35% through 2031, although treatment intent and safety considerations continue to shape adoption. WHO did not support expanded essential medicines coverage for chemotherapy-induced anemia, while ASCO and ASH continue to support ESA use in non-curative chemotherapy when reducing transfusion needs is clinically important; neurology remains limited, and perioperative anemia may gain relevance as hospital blood management protocols expand.

By End User: Care Delivery Is Gradually Moving Beyond Hospitals

Hospitals are expected to capture a 48.67% share in 2025, making them the leading end-user group in the erythropoietin drugs market due to integrated nephrology and oncology services, established monitoring, and specialist-led dose management. Dialysis centers remain the next major channel as they concentrate recurring anemia care and negotiate supplier contracts at scale, while specialty clinics bridge inpatient care and outpatient anemia management. The erythropoietin drugs market size for home care settings is projected to grow at a CAGR of 14.67% through 2031, making it the fastest-growing end-user channel. KDIGO 2026 supports this shift by recommending subcutaneous administration for non-hemodialysis CKD patients and CKD G5PD patients, strengthening self-administration pathways while keeping hospitals involved in broader care oversight.

Geography Analysis

North America held 39.86% of the erythropoietin drugs market share in 2025, maintaining its position as the largest regional contributor. The region benefits from dense dialysis infrastructure, broad reimbursement coverage, and established use of erythropoiesis-stimulating agents (ESAs) across nephrology and oncology care. The United States remains the anchor market, where originator products and biosimilars compete within a mature treatment framework, while Canada and Mexico add incremental demand shaped by public procurement and reimbursement design.

Europe and Asia-Pacific define the next phase of competition in the erythropoietin drugs market. Europe remains supported by aging populations, structured disease management, and long-standing use of originator and biosimilar ESAs, with the United Kingdom, Germany, and France remaining key markets due to established renal care pathways and protocol-driven anemia management. The UK Kidney Association’s 2025 update maintained ESAs as first-line therapy and positioned hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) as an additional option rather than a full replacement, helping preserve ESA demand in the near term. Asia-Pacific is the fastest-growing region and is forecast to advance at a 14.56% CAGR through 2031, supported by China’s dialysis expansion, India’s biosimilar supply strength, and wider anemia management efforts across developing healthcare systems. In China, 3SBio reported a 39.6% share of the domestic recombinant human erythropoietin (rhEPO) market in 2025 through its Yibiao and Epiao brands, and its March 2026 long-acting approval adds a premium layer to that franchise.

The Middle East and Africa and South America offer uneven but meaningful expansion opportunities across the erythropoietin drugs market. Demand fundamentals remain strong in these regions because chronic kidney disease burden is high and anemia treatment access remains below clinical need in many countries. North Africa and the Middle East recorded the highest age-standardized chronic kidney disease prevalence globally at 18.0%, indicating long-term demand potential even where infrastructure gaps slow immediate uptake.